132 related articles for article (PubMed ID: 29935339)
1. Characterization of killed but metabolically active uropathogenic Escherichia coli strain as possible vaccine candidate for urinary tract infection.
Jalili Z; Saleh M; Bouzari S; Pooya M
Microb Pathog; 2018 Sep; 122():184-190. PubMed ID: 29935339
[TBL] [Abstract][Full Text] [Related]
2. Photochemical inactivation as an alternative method to produce a whole-cell vaccine for uropathogenic
Westcott MM; Morse AE; Troy G; Blevins M; Wierzba T; Sanders JW
Microbiol Spectr; 2024 Mar; 12(3):e0366123. PubMed ID: 38315025
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of prevalence, immunogenicity and efficacy of FyuA iron receptor in uropathogenic Escherichia coli isolates as a vaccine target against urinary tract infection.
Habibi M; Asadi Karam MR; Bouzari S
Microb Pathog; 2017 Sep; 110():477-483. PubMed ID: 28754265
[TBL] [Abstract][Full Text] [Related]
4. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli.
Asadi Karam MR; Habibi M; Bouzari S
Mol Immunol; 2019 Apr; 108():56-67. PubMed ID: 30784763
[TBL] [Abstract][Full Text] [Related]
5. Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection.
Forsyth VS; Himpsl SD; Smith SN; Sarkissian CA; Mike LA; Stocki JA; Sintsova A; Alteri CJ; Mobley HLT
mBio; 2020 Apr; 11(2):. PubMed ID: 32345645
[TBL] [Abstract][Full Text] [Related]
6. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli.
Huttner A; Gambillara V
Clin Microbiol Infect; 2018 Oct; 24(10):1046-1050. PubMed ID: 29803843
[TBL] [Abstract][Full Text] [Related]
7. Preventing urinary tract infection: progress toward an effective Escherichia coli vaccine.
Brumbaugh AR; Mobley HL
Expert Rev Vaccines; 2012 Jun; 11(6):663-76. PubMed ID: 22873125
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with recombinant FimH fused with flagellin enhances cellular and humoral immunity against urinary tract infection in mice.
Asadi Karam MR; Oloomi M; Mahdavi M; Habibi M; Bouzari S
Vaccine; 2013 Feb; 31(8):1210-6. PubMed ID: 23306365
[TBL] [Abstract][Full Text] [Related]
9. In silico analysis and in vivo assessment of a novel epitope-based vaccine candidate against uropathogenic Escherichia coli.
Hasanzadeh S; Habibi M; Shokrgozar MA; Ahangari Cohan R; Ahmadi K; Asadi Karam MR; Bouzari S
Sci Rep; 2020 Oct; 10(1):16258. PubMed ID: 33004862
[TBL] [Abstract][Full Text] [Related]
10. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli.
Billips BK; Yaggie RE; Cashy JP; Schaeffer AJ; Klumpp DJ
J Infect Dis; 2009 Jul; 200(2):263-72. PubMed ID: 19522648
[TBL] [Abstract][Full Text] [Related]
11. Differential survival of Escherichia coli uvrA, uvrB, and uvrC mutants to psoralen plus UV-A (PUVA): Evidence for uncoupled action of nucleotide excision repair to process DNA adducts.
Lage C; Gonçalves SR; Souza LL; de Pádula M; Leitão AC
J Photochem Photobiol B; 2010 Jan; 98(1):40-7. PubMed ID: 20004108
[TBL] [Abstract][Full Text] [Related]
12. Siderophore vaccine conjugates protect against uropathogenic Escherichia coli urinary tract infection.
Mike LA; Smith SN; Sumner CA; Eaton KA; Mobley HL
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13468-13473. PubMed ID: 27821778
[TBL] [Abstract][Full Text] [Related]
13. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
Habibi M; Asadi Karam MR; Bouzari S
APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
[TBL] [Abstract][Full Text] [Related]
14. [Urinary tract infections, immunity, and vaccination].
Luna-Pineda VM; Ochoa S; Cruz-Córdova A; Cázares-Domínguez V; Vélez-González F; Hernández-Castro R; Xicohtencatl-Cortes J
Bol Med Hosp Infant Mex; 2018; 75(2):67-78. PubMed ID: 29658949
[TBL] [Abstract][Full Text] [Related]
15. Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine.
Uehling DT; Hopkins WJ; James LJ; Balish E
J Urol; 1994 Jan; 151(1):214-6. PubMed ID: 8254817
[TBL] [Abstract][Full Text] [Related]
16. Vaccine Development for Urinary Tract Infections: Where Do We Stand?
Magistro G; Stief CG
Eur Urol Focus; 2019 Jan; 5(1):39-41. PubMed ID: 30093359
[TBL] [Abstract][Full Text] [Related]
17. [Development of a killed but metabolically active anthracis vaccine candidate strain].
Shen F; Yuan S; Zhan D; Wang Y; Ren M; Tao H; Wang P; Wang L; Chen D; Liu C
Sheng Wu Gong Cheng Xue Bao; 2011 May; 27(5):781-9. PubMed ID: 21845845
[TBL] [Abstract][Full Text] [Related]
18. Uropathogenic Escherichia coli virulence and innate immune responses during urinary tract infection.
Ulett GC; Totsika M; Schaale K; Carey AJ; Sweet MJ; Schembri MA
Curr Opin Microbiol; 2013 Feb; 16(1):100-7. PubMed ID: 23403118
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic Necrotizing Factor-1 (CNF1) does not promote E. coli infection in a murine model of ascending pyelonephritis.
Michaud JE; Kim KS; Harty W; Kasprenski M; Wang MH
BMC Microbiol; 2017 May; 17(1):127. PubMed ID: 28545489
[TBL] [Abstract][Full Text] [Related]
20. Virulence factors of uropathogenic Escherichia coli of urinary tract infections and asymptomatic bacteriuria in children.
Yun KW; Kim HY; Park HK; Kim W; Lim IS
J Microbiol Immunol Infect; 2014 Dec; 47(6):455-61. PubMed ID: 24064288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
